ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Healx links with CTF to develop neurofibromatosis therapies
April 16, 2020Cambridge, UK-based Healx has formed a new partnership with US and Europe-based patient group the Children’s Tumor Foundation (CTF) to progress new AI-derived therapies for neurofibromatosis (NF). -
Selumetinib granted US Breakthrough Therapy Designation in neurofibromatosis type 1
April 03, 2019The Association of the British Pharmaceutical Industry has called for a temporary ban on drugs exports in the event of a no-deal Brexit to prevent the NHS being hit by shortages… -
AZ and MSD get orphan designation for neurofibromatosis drug
August 06, 2018The EMA has granted orphan designation to AstraZeneca and MSD's selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).
Pharma Sources Insight January 2025
